Netherlands-based Qiagen NV has acquired Corbett Life Science, a privately-held developer, manufacturer and distributor of life sciences instrumentation headquartered in Sydney, Australia. The transaction is valued at around $66.0 million in cash (subject to certain customary purchase price adjustments), $4.0 million in restricted Qiagen common stock and performance and development milestone payments and other contingencies of up to about $65.0 million over the next four years, for a total of up to $135.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze